PMID- 37530897
OWN - NLM
STAT- MEDLINE
DCOM- 20230803
LR  - 20230821
IS  - 1573-3890 (Electronic)
IS  - 1573-3882 (Print)
IS  - 1573-3882 (Linking)
VI  - 19
IP  - 8
DP  - 2023 Aug 2
TI  - Behavioral metabolomics: how behavioral data can guide metabolomics research on 
      neuropsychiatric disorders.
PG  - 69
LID - 10.1007/s11306-023-02034-6 [doi]
LID - 69
AB  - INTRODUCTION: Metabolomics produces vast quantities of data but determining which 
      metabolites are the most relevant to the disease or disorder of interest can be 
      challenging. OBJECTIVES: This study sought to demonstrate how behavioral models 
      of psychiatric disorders can be combined with metabolomics research to overcome 
      this limitation. METHODS: We designed a preclinical, untargeted metabolomics 
      procedure, that focuses on the determination of central metabolites relevant to 
      substance use disorders that are (a) associated with changes in behavior produced 
      by acute drug exposure and (b) impacted by repeated drug exposure. Untargeted 
      metabolomics analysis was carried out on liquid chromatography-mass spectrometry 
      data obtained from 336 microdialysis samples. Samples were collected from the 
      medial striatum of male Sprague-Dawley (N = 21) rats whilst behavioral data were 
      simultaneously collected as part of a (+/-)-3,4-methylenedioxymethamphetamine 
      (MDMA)-induced behavioral sensitization experiment. Analysis was conducted by 
      orthogonal partial least squares, where the Y variable was the behavioral data, 
      and the X variables were the relative concentrations of the 737 detected 
      features. RESULTS: MDMA and its derivatives, serotonin, and several 
      dopamine/norepinephrine metabolites were the greatest predictors of acute 
      MDMA-produced behavior. Subsequent univariate analyses showed that repeated MDMA 
      exposure produced significant changes in MDMA metabolism, which may contribute to 
      the increased abuse liability of the drug as a function of repeated exposure. 
      CONCLUSION: These findings highlight how the inclusion of behavioral data can 
      guide metabolomics data analysis and increase the relevance of the results to the 
      phenotype of interest.
CI  - (c) 2023. The Author(s).
FAU - van de Wetering, Ross
AU  - van de Wetering R
AUID- ORCID: 0000-0002-1387-444X
AD  - School of Psychology, Victoria University of Wellington, Wellington, New Zealand. 
      ross.vandewetering@vuw.ac.nz.
FAU - Vorster, Jan A
AU  - Vorster JA
AUID- ORCID: 0000-0002-7764-4053
AD  - School of Chemical and Physical Sciences, Victoria University of Wellington, 
      Wellington, New Zealand.
FAU - Geyrhofer, Sophie
AU  - Geyrhofer S
AUID- ORCID: 0000-0001-5687-2586
AD  - School of Chemical and Physical Sciences, Victoria University of Wellington, 
      Wellington, New Zealand.
FAU - Harvey, Joanne E
AU  - Harvey JE
AUID- ORCID: 0000-0002-7658-7421
AD  - School of Chemical and Physical Sciences, Victoria University of Wellington, 
      Wellington, New Zealand.
FAU - Keyzers, Robert A
AU  - Keyzers RA
AUID- ORCID: 0000-0002-7786-8313
AD  - School of Chemical and Physical Sciences, Victoria University of Wellington, 
      Wellington, New Zealand.
FAU - Schenk, Susan
AU  - Schenk S
AD  - School of Psychology, Victoria University of Wellington, Wellington, New Zealand.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230802
PL  - United States
TA  - Metabolomics
JT  - Metabolomics : Official journal of the Metabolomic Society
JID - 101274889
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - 333DO1RDJY (Serotonin)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Rats
MH  - Male
MH  - Animals
MH  - *N-Methyl-3,4-methylenedioxyamphetamine/metabolism/pharmacology
MH  - Metabolomics/methods
MH  - Rats, Sprague-Dawley
MH  - Serotonin
MH  - Dopamine/metabolism
PMC - PMC10397151
OTO - NOTNLM
OT  - Addiction
OT  - Behavior
OT  - LCMS
OT  - MDMA
OT  - Metabolomics
OT  - Sensitization
COIS- The authors have no relevant financial or non-financial interests to disclose.
EDAT- 2023/08/02 13:08
MHDA- 2023/08/03 06:43
PMCR- 2023/08/02
CRDT- 2023/08/02 11:07
PHST- 2023/03/07 00:00 [received]
PHST- 2023/07/19 00:00 [accepted]
PHST- 2023/08/03 06:43 [medline]
PHST- 2023/08/02 13:08 [pubmed]
PHST- 2023/08/02 11:07 [entrez]
PHST- 2023/08/02 00:00 [pmc-release]
AID - 10.1007/s11306-023-02034-6 [pii]
AID - 2034 [pii]
AID - 10.1007/s11306-023-02034-6 [doi]
PST - epublish
SO  - Metabolomics. 2023 Aug 2;19(8):69. doi: 10.1007/s11306-023-02034-6.